Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Clearmind Medicine Inc. Common Shares (CMND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: CMND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.25% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -1.31 | 52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 |
52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.23% | Return on Equity (TTM) -139.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168145 | Price to Sales(TTM) - |
Enterprise Value 168145 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.79 | Shares Outstanding 5379440 | Shares Floating 4864790 |
Shares Outstanding 5379440 | Shares Floating 4864790 | ||
Percent Insiders 2.8 | Percent Institutions 11.19 |
Upturn AI SWOT
Clearmind Medicine Inc. Common Shares
Company Overview
History and Background
Clearmind Medicine Inc. is a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major health challenges. Founded in 2020, it's relatively young and has been rapidly advancing its research and development efforts.
Core Business Areas
- Drug Development: Developing novel psychedelic-derived therapeutics, primarily focusing on CMND-100, a proprietary compound for treating Alcohol Use Disorder (AUD) and Binge Eating Disorder (BED).
- Clinical Trials: Conducting preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Securing patents and intellectual property rights for its compounds and formulations.
Leadership and Structure
The company has a management team with experience in biotechnology, pharmaceuticals, and clinical development. Details on specific roles and organizational structure are available in their investor relations materials.
Top Products and Market Share
Key Offerings
- CMND-100: CMND-100 is Clearmind's lead drug candidate, targeting AUD and BED. It is currently in clinical development (Phase I/II trials). Market share is currently non-applicable as the product is not yet commercialized. Competitors in the treatment of AUD include companies developing medications like naltrexone and acamprosate (e.g., Alkermes, Teva Pharmaceuticals). Competitors in the treatment of BED include companies marketing lisdexamfetamine dimesylate (Vyvanse) (e.g., Takeda).
Market Dynamics
Industry Overview
The psychedelic medicine industry is experiencing rapid growth, driven by increasing research demonstrating the potential therapeutic benefits of psychedelics for various mental health conditions. There's growing interest from investors and pharmaceutical companies.
Positioning
Clearmind is positioned as a drug development company focusing on specific niche areas within the psychedelic medicine space, primarily AUD and BED. Its competitive advantage lies in its proprietary compound CMND-100 and its focus on these underserved markets.
Total Addressable Market (TAM)
The TAM for AUD and BED treatments is estimated to be billions of dollars annually. Clearmind's positioning allows it to target a portion of this TAM by developing novel and potentially more effective therapies.
Upturn SWOT Analysis
Strengths
- Proprietary compound CMND-100
- Focus on underserved markets (AUD and BED)
- Experienced management team
- Intellectual property portfolio
Weaknesses
- Early-stage company with limited revenue
- Dependence on successful clinical trial outcomes
- High cash burn rate typical of biotech startups
- Susceptibility to regulatory hurdles
Opportunities
- Positive clinical trial results could drive significant value
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new indications for CMND-100
- Increasing acceptance of psychedelic medicine
Threats
- Clinical trial failures
- Regulatory delays or disapproval
- Competition from other companies developing similar therapies
- Changes in public perception of psychedelics
Competitors and Market Share
Key Competitors
- ALKS
- TEVA
- TAK
Competitive Landscape
Clearmind faces competition from established pharmaceutical companies that develop and market traditional treatments for AUD and BED, and emerging companies in the psychedelic medicine space, some of which are more advanced in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is relatively new. The primary focus has been on advancing CMND-100 through preclinical and clinical development.
Future Projections: Future growth is highly dependent on the success of clinical trials. Analyst estimates are not readily available for micro-cap companies like Clearmind. Successful Phase II trials could lead to significant stock appreciation.
Recent Initiatives: Recent initiatives include advancing CMND-100 into Phase I/II clinical trials for AUD and BED and expanding their intellectual property portfolio.
Summary
Clearmind Medicine is an early-stage biotech company with potential in the psychedelic medicine space. The company's lead drug candidate, CMND-100, targets AUD and BED, and is in clinical development. Successful trial outcomes, partnerships, and continued IP development will be critical for future growth. The company is exposed to clinical trial risks and regulatory hurdles, and faces competition from established pharmaceutical companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investing in early-stage biotech companies involves significant risks. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearmind Medicine Inc. Common Shares
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2021-08-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.